ACADIA PHARMACEUTICALS INC. Cash and Cash Equivalents, Period Increase (Decrease)
ACADIA PHARMACEUTICALS INC. (ACAD) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$94.20 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-27.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-02-27
- ACADIA PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$43.20M, a 534.54% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$31.17M, a 242.31% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$13.59M.
- ACADIA PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$6.24M, a 108.53% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$94.20M, a 253.22% decline from fiscal 2016.
- ACADIA PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $61.48M, a 52.62% increase from fiscal 2015.
- ACADIA PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $40.28M, a 19.67% decline from fiscal 2014.
- ACADIA PHARMACEUTICALS INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $50.15M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$43.20M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$74.37M derived: sum of 2 quarters · filed 2018-02-27 | -$87.97M derived: sum of 3 quarters · filed 2018-02-27 | -$94.20M 10-K · filed 2018-02-27 |
| 2017-09-30 | -$31.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$44.77M derived: sum of 2 quarters · filed 2017-11-07 | -$51.00M 10-Q · filed 2017-11-07 | -$41.06M derived: sum of 4 quarters · filed 2018-02-27 |
| 2017-06-30 | -$13.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$19.83M 10-Q · filed 2017-08-08 | -$9.89M derived: sum of 3 quarters · filed 2018-02-27 | $12.02M derived: sum of 4 quarters · filed 2018-02-27 |
| 2017-03-31 | -$6.24M 10-Q · filed 2017-05-09 | $3.70M derived: sum of 2 quarters · filed 2018-02-27 | $25.61M derived: sum of 3 quarters · filed 2018-02-27 | -$17.84M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-12-31 | $9.94M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $31.85M derived: sum of 2 quarters · filed 2018-02-27 | -$11.60M derived: sum of 3 quarters · filed 2018-02-27 | $61.48M 10-K · filed 2018-02-27 |
| 2016-09-30 | $21.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$21.54M derived: sum of 2 quarters · filed 2017-11-07 | $51.54M 10-Q · filed 2017-11-07 | $82.88M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | -$43.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $29.64M 10-Q · filed 2017-08-08 | $60.98M derived: sum of 3 quarters · filed 2018-02-27 | $38.56M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $73.08M 10-Q · filed 2017-05-09 | $104.42M derived: sum of 2 quarters · filed 2018-02-27 | $82.01M derived: sum of 3 quarters · filed 2018-02-27 | $98.80M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $31.34M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $8.93M derived: sum of 2 quarters · filed 2018-02-27 | $25.71M derived: sum of 3 quarters · filed 2018-02-27 | $40.28M 10-K · filed 2018-02-27 |
| 2015-09-30 | -$22.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | -$5.63M derived: sum of 2 quarters · filed 2016-11-07 | $8.95M 10-Q · filed 2016-11-07 | $34.43M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-06-30 | $16.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $31.36M 10-Q · filed 2016-08-04 | $56.84M derived: sum of 3 quarters · filed 2017-02-28 | $79.51M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-03-31 | $14.57M 10-Q · filed 2016-05-05 | $40.05M derived: sum of 2 quarters · filed 2017-02-28 | $62.73M derived: sum of 3 quarters · filed 2017-02-28 | -$20.03M derived: sum of 4 quarters · filed 2017-02-28 |
| 2014-12-31 | $25.48M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $48.16M derived: sum of 2 quarters · filed 2017-02-28 | -$34.60M derived: sum of 3 quarters · filed 2017-02-28 | $50.15M 10-K · filed 2017-02-28 |
| 2014-09-30 | $22.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | -$60.09M derived: sum of 2 quarters · filed 2015-11-05 | $24.66M 10-Q · filed 2015-11-05 | $24.57M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | -$82.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $1.99M 10-Q · filed 2015-08-06 | $1.90M derived: sum of 3 quarters · filed 2016-02-29 | -$10.55M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $84.75M 10-Q · filed 2015-05-07 | $84.65M derived: sum of 2 quarters · filed 2016-02-29 | $72.21M derived: sum of 3 quarters · filed 2016-02-29 | $78.02M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | -$96.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$12.54M derived: sum of 2 quarters · filed 2016-02-29 | -$6.73M derived: sum of 3 quarters · filed 2016-02-29 | -$46.19M 10-K · filed 2016-02-29 |
| 2013-09-30 | -$12.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$6.63M derived: sum of 2 quarters · filed 2014-11-10 | -$46.10M 10-Q · filed 2014-11-10 | $3.79M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | $5.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | -$33.65M 10-Q · filed 2014-08-05 | $16.23M derived: sum of 3 quarters · filed 2015-02-26 | $15.04M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | -$39.46M 10-Q · filed 2014-05-06 | $10.42M derived: sum of 2 quarters · filed 2015-02-26 | $9.23M derived: sum of 3 quarters · filed 2015-02-26 | $12.88M derived: sum of 4 quarters · filed 2015-02-26 |
| 2012-12-31 | $49.88M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $48.69M derived: sum of 2 quarters · filed 2015-02-26 | $52.34M derived: sum of 3 quarters · filed 2015-02-26 | $51.01M 10-K · filed 2015-02-26 |
| 2012-09-30 | -$1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | $2.46M derived: sum of 2 quarters · filed 2013-11-06 | $1.13M 10-Q · filed 2013-11-06 | -$301.00K derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $3.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $2.32M 10-Q · filed 2013-08-06 | $891.00K derived: sum of 3 quarters · filed 2014-02-27 | $1.19M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | -$1.33M 10-Q · filed 2013-05-07 | -$2.76M derived: sum of 2 quarters · filed 2014-02-27 | -$2.46M derived: sum of 3 quarters · filed 2014-02-27 | -$1.27M derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | -$1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | -$1.13M derived: sum of 2 quarters · filed 2014-02-27 | $60.00K derived: sum of 3 quarters · filed 2014-02-27 | $40.00K 10-K · filed 2014-02-27 |
| 2011-09-30 | $297.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-05 | $1.49M derived: sum of 2 quarters · filed 2012-11-05 | $1.47M 10-Q · filed 2012-11-05 | -$1.34M derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-06-30 | $1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $1.17M 10-Q · filed 2012-08-08 | -$1.64M derived: sum of 3 quarters · filed 2013-03-12 | -$791.00K derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-03-31 | -$20.00K 10-Q · filed 2012-05-08 | -$2.83M derived: sum of 2 quarters · filed 2013-03-12 | -$1.98M derived: sum of 3 quarters · filed 2013-03-12 | |
| 2010-12-31 | -$2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | -$1.96M derived: sum of 2 quarters · filed 2013-03-12 | -$11.27M 10-K · filed 2013-03-12 | |
| 2010-09-30 | $845.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | -$8.47M 10-Q · filed 2011-11-09 | ||
| 2010-06-30 | -$9.31M 10-Q · filed 2011-08-10 | |||
| 2009-12-31 | -$3.05M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |